SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024 [Yahoo! Finance]
SOPHiA GENETICS SA - Ordinary Shares (SOPH)
Company Research
Source: Yahoo! Finance
BOSTON and ROLLE, Switzerland Sept. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company's work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio's extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to identify patients with ecDNA amplified tumors using the SOPHiA DDM™ Platform. The two companies collaborated with precision medicine clinical research organization (CRO) Precision for Medicine, which contributes its state-of-the-art, CAP-accredited, CLIA-certified laboratory services to Boundless Bio's POTENTIATE Phase 1/2 clinical trial by successfully validating a proprietary workflow to process patient samples. It is well established that oncogenic alterations, such as mutations and fusions, can lead to malignant cellular growth that result
Show less
Read more
Impact Snapshot
Event Time:
SOPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOPH alerts
High impacting SOPHiA GENETICS SA - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
SOPH
News
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS Launches Comprehensive MRD Tracking Capabilities [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS Launches Comprehensive MRD Tracking CapabilitiesPR Newswire
- SOPHiA GENETICS SA (NASDAQ: SOPH) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
SOPH
Earnings
- 11/5/24 - Miss
SOPH
Sec Filings
- 1/27/25 - Form 144
- 1/27/25 - Form 144
- 1/24/25 - Form 144
- SOPH's page on the SEC website